This is a good article, I don't agree with your conclusion though but that's because I'm optimistic about pona going into the europe decision. My only criticism of the article is that you're reading a short analytic chart wrong. That number from short analytics, to my knowledge, is the % of the shares on that specific day that were sold short vs. covered. It's not the outstanding short interest, get that number from shortsqueeze. To prove my point, look at september 24 to the 25th of your chart, short interest could not swing from 10% to 50% in one day, that would require an absurd volume.

Maybe it's just me, but I can't make out any of the details on the chart posted-the resolution is too low. Also, it seems like this article should have been posted on Wednesday of last week, because the significant fall on heavy volume might change the author's outlook- or at least it should have been commented on.

amarin was modified fish oils, so it was denied NCE because, the fda was specific, it was unclear which of the oils in the mixture was the active ingredient. I'm guessing that ferric citrate is more or less one chemical entity, not a mixture.

What is the current state of the stock buyback? I recall that CREE was investing 300 million in their own stock- is that completed, ongoing and will that be increased in future quarters? I think they were buying in the 45 dollar range last quarter.

Not sure how you're finding these, but TSLA isn't down in after hours, it's up. Your algorithm or whatever you used picked up on a late institutional trade that was just printed after hours. This isn't the first time this happened either...

If I recall correctly, the authors only count trades that are opened and closed within the same day to characterize Day Traders. Trades that someone might open and let run because its profitable were not taken into account, skewing the finding.

Retrophin: An Attractive Short Candidate Due To Numerous Red Flags [View article]

So why raise guidance repeatedly? How can they miss on their first and second guidance and have to raise it repeatedly? I can see one raise once the deal went through. Also, do you think there will be any repercussions from Martin's tweets?

I'm not sure whose hoping is going to die. Tesla is at $222 in germany the morning you wrote this, after Morgan stanley upgraded them with a $320 price target. Hopefully the market opens and we go up from there.

Author, you say Positive results in previous trials, combined with the rich patient data InterMune has been collecting throughout the countries where Esbriet is already marketed, make it very likely that nintedanib will demonstrate statistical significance in ASCEND trials, and will be approved by the FDA next year.

Did you really mean Nintedanib? Isn't that their competitors drug? Did you mean pirfenidone?